Tofacitinib to Jockey With Anti-TNFs for RA Role
20:00 EDT 20 Jun 2012 | Elsevier Business Intelligence
If approved for treating rheumatoid arthritis, Pfizer’s oral, small-molecule drug may start to muscle in on the treatment turf now occupied by antitumor necrosis factor drugs, some experts predicted at rheumatology conference.
Original Article: Tofacitinib to Jockey With Anti-TNFs for RA Role
More From BioPortfolio on "Tofacitinib to Jockey With Anti-TNFs for RA Role"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
